User profiles for Jamie Lopez Bernal
 | Lopez Bernal, JamiePublic Health England Verified email at lshtm.ac.uk Cited by 21284 |
Early effectiveness of COVID-19 vaccination with BNT162b2 mRNA vaccine and ChAdOx1 adenovirus vector vaccine on symptomatic disease, hospitalisations and …
Objectives To estimate the real-world effectiveness of the Pfizer/BioNTech BNT162b2 vaccine
and Astrazeneca ChAdOx1 vaccine against Confirmed COVID-19, hospitalisations and …
and Astrazeneca ChAdOx1 vaccine against Confirmed COVID-19, hospitalisations and …
[HTML][HTML] Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
Background The B. 1.617. 2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
…, M Patel, A Charlett, JL Bernal… - …, 2020 - eurosurveillance.org
Severe acute respiratory syndrome coronavirus 2 viral load in the upper respiratory tract
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
peaks around symptom onset and infectious virus persists for 10 days in mild-to-moderate …
Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study
…, RJ Harris, R Hope, J Lopez-Bernal… - The Lancet Infectious …, 2022 - thelancet.com
Background The SARS-CoV-2 delta (B.1.617.2) variant was first detected in England in March,
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
2021. It has since rapidly become the predominant lineage, owing to high transmissibility. …
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre …
Background BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have
been rapidly rolled out in the UK from December, 2020. We aimed to determine the factors …
been rapidly rolled out in the UK from December, 2020. We aimed to determine the factors …
Effectiveness of Covid-19 vaccines against the B. 1.617. 2 (Delta) variant
J Lopez Bernal, N Andrews, C Gower… - … England Journal of …, 2021 - Mass Medical Soc
Background The B.1.617.2 (delta) variant of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has …
Duration of protection against mild and severe disease by Covid-19 vaccines
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
the virus that causes coronavirus disease 2019 (Covid-19), have been used since …
Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1. 529) and delta (B. 1.617. 2) variants in England: a cohort …
Background The omicron variant (B.1.1.529) of SARS-CoV-2 has demonstrated partial vaccine
escape and high transmissibility, with early studies indicating lower severity of infection …
escape and high transmissibility, with early studies indicating lower severity of infection …
Covid-19 vaccine effectiveness against the Omicron (B. 1.1. 529) variant
Background A rapid increase in coronavirus disease 2019 (Covid-19) cases due to the
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 in highly …
Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England …
Objective To estimate the real world effectiveness of the Pfizer-BioNTech BNT162b2 and
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …
Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed covid-19 symptoms (including the …